Particle.news
Download on the App Store
9 ARTICLES
·
3mo ago

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

It uses a dual GIP/GLP-1 mechanism shown to cut body weight by about a quarter in trials.

Se inyecta una vez por semana.
El fármaco Mounjaro, cuyo principio activo es la Tirzepatida, se presenta como una nueva herramienta terapéutica para el descenso de peso en la Argentina.
Mounjaro, a base de tirzepatida, se presenta en el país como un inyectable semanal de doble acción hormonal para tratar obesidad y diabetes tipo 2.
Según la Organización Panamericana de la Salud, la obesidad y el sobrepeso en las Américas aumentaron del 44,4% en 1990 al 67,5% en 2022, con proyecciones de alcanzar el 73,2% en 2030. 

Overview

  • Adium has begun market availability in December with 2.5 mg and 5 mg prefilled pens, with higher-dose presentations expected next year.
  • ANMAT authorizes use for adults with obesity (BMI ≥30) or overweight with comorbidity (BMI ≥27) and for type 2 diabetes, given once weekly in stepped doses from 2.5 mg to 15 mg.
  • SURMOUNT and SURPASS studies reported approximately 25–26% weight loss and additional improvements in waist circumference, blood pressure, triglycerides and fatty liver.
  • The most common adverse effects are gastrointestinal symptoms such as nausea, vomiting and diarrhea, which clinicians report typically ease over time.
  • Retail pricing is high, with a four-dose 5 mg pack listed at ARS 783,858.40, and Adium says patients with prescriptions may receive discounts of up to about 30%.